PDGFRA and gastrointestinal stromal tumor: The launch of avapritinib resulted in an unprecedented, durable clinical benefit to GIST patients with PDGFRA D842V-mutation.457–459 However, the overall effects of avapritinib were not superior to regorafenib in patients with locally advanced unresectable or metastatic GIST in a randomized VOYAGER phase III study (NCT02508532).460 The phase IV clinical trial has been planned to assess the effect of avapritinib on a larger group of participants.